Guidance and Best Practice

Over the past 20-years, there has been an increased focus on the use of newer biologic medication in people with severe asthma that is not controlled with usual asthma medication. Although there are currently six biologics (January 2025) licensed for use in severe asthma, estimates suggest that of the 60,000 people potentially eligible for biologics in England, only 8,000-10,000 are on these treatments. 

Primary Care Respiratory Society (PCRS) position statement

Consider ways in which climate change and the resulting extreme weather can worsen symptoms and trigger exacerbations.

2024 marked a pivotal change in the management of asthma in the UK with the publication of a joint British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) guideline. This guideline, ‘Asthma: diagnosis, monitoring and chronic asthma management’, has the potential to be the paradigm shift that is needed to improve asthma care in the UK. 

Spirometry should be delivered and technically reported by registered healthcare professionals with an appropriate level of expertise and experience.

The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe - four times that of Italy or the Netherlands. This is unsurprising, considering many patients still rely on their blue inhalers alone.However:• Blue inhalers don’t treat inflammation• Brown inhalers don’t relieve symptoms quicklyFirst and foremost, the best inhaler is the inhaler the patient will use and identifying what this is should actively involve the patient.

New BTS/SIGN/NICE Guideline on Asthma: diagnosis, monitoring and chronic asthma management 2024

This is a high-level summary of what the new BTS/NICE/SIGN Asthma: diagnosis monitoring and chronic asthma management guideline means for you as a primary healthcare professional and what steps you need to take to implement it effectively.